Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025;24(2):158-163.
doi: 10.2174/0118715273304077240603115521.

Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series

Affiliations
Case Reports

Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series

Giovanni Di Mauro et al. CNS Neurol Disord Drug Targets. 2025.

Abstract

Introduction: Refractory and super-refractory status epilepticus are medical emergencies that must be promptly treated in consideration of their high mortality and morbidity rate. Nevertheless, the available evidence of effective treatment for these conditions is scarce. Among novel antiseizure medications (ASMs), highly purified cannabidiol (hpCBD) has shown noteworthy efficacy in reducing seizures in Lennox-Gastaut syndrome, Dravet syndrome, and Tuberous Sclerosis Complex.

Case presentation: Here, we present two cases of effective use of hpCBD in both refractory and super- refractory status epilepticus. The administration of the nasogastric tube permitted the resolution of status epilepticus without adverse events. At 6-month follow-up, both patients were on hpCBD treatment, which continued to be efficacious for treating seizures.

Conclusion: According to our experience, hpCBD should be taken into consideration as an add-on therapy of RSE and SRSE while also considering the possibility of maintaining this treatment during the follow-up of patients. However, more studies and real-world experiences are needed to better understand its effectiveness in this setting and the interaction with other ASMs.

Keywords: Status epilepticus; anti-seizure medication; emergency; epilepsy; lennox-gastaut syndrome.; seizure.

PubMed Disclaimer

References

    1. Trinka E.; Leitinger M.; Management of Status epilepticus, refractory status epilepticus, and super-refractory status epilepticus. Continuum (Minneap Minn) 2022,28(2),559-602 - DOI - PubMed
    1. Brophy G.M.; Bell R.; Claassen J.; Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012,17(1),3-23 - DOI - PubMed
    1. Lowenstein D.H.; The management of refractory status epilepticus: An update. Epilepsia 2006,47(s1)(Suppl. 1),35-40 - DOI - PubMed
    1. Kirmani B.F.; Au K.; Ayari L.; John M.; Shetty P.; Delorenzo R.J.; Super-refractory status epilepticus: Prognosis and recent advances in management. Aging Dis 2021,12(4),1097-1119 - DOI
    1. Rai S.; Drislane F.W.; Treatment of refractory and super-refractory status epilepticus. Neurotherapeutics 2018,15(3),697-712 - DOI - PubMed

Publication types

MeSH terms